Anzeige
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DMC3 | ISIN: NL0015000YE1 | Ticker-Symbol: 0N6A
Frankfurt
24.04.25
15:29 Uhr
0,061 Euro
-0,001
-1,13 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
TME PHARMA NV Chart 1 Jahr
5-Tage-Chart
TME PHARMA NV 5-Tage-Chart
RealtimeGeldBriefZeit
0,0640,06724.04.

Aktuelle News zur TME PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
10.04.TME Pharma N.V.: TME Pharma Provides Update on Resources Allocated to the Liquidity Contract With Invest Securities329Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment...
► Artikel lesen
28.03.TME Pharma N.V.: TME Pharma Provides Results of Fifth Exercise of Warrants Z643556 Warrants Z were exercised resulting in the issuance of 695 new ordinary shares Outstanding 2,810,092 Warrants Z remain exercisable until June 20, 2025, with potential to raise up to...
► Artikel lesen
13.03.TME Pharma N.V.: TME Pharma Announces Filing of Patents for Use of CCL2 Inhibitor NOX-E36 in Ophthalmology and Presentation at ARVO 2025 of Preclinical Data Showing Benefit in Glaucoma Filtration Surgery428TME Pharma and Singapore Eye Research Institute (SERI) file new patent applications covering NOX-E36 for treatment of glaucoma filtration surgery and other ophthalmic diseases Preclinical...
► Artikel lesen
17.02.TME Pharma N.V.: TME Pharma CEO Message430Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancer by targeting the tumor...
► Artikel lesen
29.01.TME Pharma N.V.: TME Pharma Announces Collaboration with aimed analytics for AI-Driven Drug Discovery and Optimization599New Capabilities aim to strengthen corporate profile for strategic transactions and reinforce ongoing partnering discussions Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME)...
► Artikel lesen
TME PHARMA Aktie jetzt für 0€ handeln
20.01.TME Pharma N.V.: TME Pharma: Half-yearly Report on the Liquidity Contract With Invest Securities421Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment...
► Artikel lesen
23.12.24TME Pharma: Kapitalmaßnahme vollständig platziert660Mitte Dezember hat TME Pharma eine Kapitalerhöhung angekündigt. Jetzt kommt die Vollzugsmeldung. Alle angebotenen 52 Millionen Aktien sind platziert worden. Altaktionäre konnten für vier Aktien fünf...
► Artikel lesen
23.12.24TME Pharma N.V.: TME Pharma Announces Successful Completion of €2.6 Million Public Offer With Strong Shareholder Support32277.52% of the public offer was subscribed by existing shareholders using their pro rata subscription rights, totaling €2,015,549.10 and representing 40,310,982 new ordinary shares The remaining...
► Artikel lesen
20.12.24TME Pharma Provides Results of Fourth Exercise of Warrants Z513432 Warrants Z were exercised resulting in the issuance of 540 new ordinary shares Outstanding 2,810,648 Warrants Z remain exercisable until June 20, 2025, with potential to raise up to...
► Artikel lesen
12.12.24TME Pharma: Garantierte Kapitalerhöhung für Liquiditätsdecke544Das Biotech-Unternehmen TME Pharma startet am 12. Dezember 2024 ein öffentliches Angebot über 2,6 Millionen Euro, das ausschließlich bestehenden Aktionären vorbehalten ist. Anteilseigner, die am Stichtag...
► Artikel lesen
12.12.24TME Pharma N.V.: TME Pharma Announces the Launch of Fully Guaranteed Public Offer for €2.6 Million Open Only to Shareholders to Enable Completion of Strategic Transactions by June 2025449Launch of a public offer on December 12, 2024, with a priority period from December 12 to December 18, 2024 only for shareholders of TME Pharma on record date of December 11, 20241, without preferential...
► Artikel lesen
04.12.24TME Pharma N.V.: TME Pharma Announces Corporate Strategy Update and Upcoming €2.6 Million Guaranteed Financing With Intention to Launch Public Offer Open Only to Shareholders to Enable Completion of Transactions ...808TME Pharma will focus its resources in the next seven months towards the newly prioritized strategic aims of completing a spin-out or a strategic transaction in addition to licensing or financing...
► Artikel lesen
23.11.24TME Pharma N.V.: TME Pharma Announces Poster Presentation by U.S. National Cancer Institute on CXCL12 Inhibition by NOX-A12 in Glioblastoma at 2024 SNO Annual Meeting243Presentation highlights synergistic effect of combining NOX-A12's anti-CXCL12 activity with immune checkpoint inhibition in brain cancer models inducing a favorable tumor microenvironment (TME)...
► Artikel lesen
31.10.24TME Pharma N.V.: TME Pharma Awarded €2.4 Million German Federal Grant to Support NOX-A12 Phase 2 Trial in Brain Cancer931The grant program run by the German Federal Ministry of Education and Research (BMBF) supports SMEs working on innovative projects in biomedicine Non-dilutive support for planned phase...
► Artikel lesen
18.10.24TME Pharma N.V.: TME Pharma Reports H1 2024 Financial Results and Provides Business and Clinical Update750Statistically significant survival benefit of NOX-A12 bevacizumab radiotherapy for glioblastoma patients compared to both standard of care and NOX-A12 radiotherapy demonstrated by latest NOX-A12...
► Artikel lesen
18.10.24TME Pharma Reports H1 2024 Financial Results and Provides Business and Clinical Update599BERLIN--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by...
► Artikel lesen
30.09.24TME Pharma N.V.: TME Pharma Announces Appointment of Alexandra Glucksmann to Supervisory Board470Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment...
► Artikel lesen
29.09.24HV-Kalender: Aktionärs-Versammlungen u.a. bei DEMIRE, GIEAG, TME Pharma1.275Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen....
► Artikel lesen
27.09.24TME Pharma N.V.: TME Pharma Provides Results of Third Exercise of Warrants Z5561,552 Warrants Z were exercised resulting in the issuance of 1,940 new ordinary shares Outstanding 2,811,080 Warrants Z remain exercisable until June 20, 2025, with potential to raise up...
► Artikel lesen
19.09.24TME Pharma N.V.: TME Pharma Announces Acceptance of the NCI'S Abstract on NOX-A12 in Glioblastoma for Presentation at the SNO 2024 Annual Meeting691Presentation will feature the results of the work conducted by the National Cancer Institute on inhibition of CXCL12 Research has been conducted by NCI under an agreement established with...
► Artikel lesen
Seite:  Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1